Latest Financial Results

Q1 2017

Quarter Ended Mar 31, 2017

Stock Information

Symbol

NASDAQ: CUR

Price

Change

Volume

Market Cap

Day Low/High

52 week Low/High

Company Overview

Neuralstem is a biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need.  Our lead asset, NSI-189, is a new chemical entity in Phase 2 clinical development for major depressive disorder (MDD). Our transplantational stem cell asset, NSI-566, is a spinal cord-derived neural stem cell line being tested in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS).  These product candidates are based on the company’s proprietary neural stem cell technology.

Contact Information

Investor Relations
Danielle Spangler
Director, Investor Relations
T: 301-366-1481
dspangler@neuralstem.com

Argot Partners
Kimberly Minarovich
T: 212-600-1902
kimberly@argotpartners.com

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 718-921-8200

Auditor
Dixon Hughes Goodman LLP
809 Glen Eagles Court
Suite 200
Baltimore, MD 21286
T: 410-838-8000
F: 410-296-4815

Public Relations
LDR Communications
Lori Rosen
Public Relations
T: 917-553-6808
lori@ldrcommunications.com